These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10622092)

  • 1. Management of hypertension and its sequelae with ACE inhibitors: biochemical, pharmacological and clinical aspects.
    Rangoonwala B; Rosenthal I
    Int J Clin Pract; 1998 Oct; 52(7):492-500. PubMed ID: 10622092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors in cardiovascular disease. Which patient? Which drug? Which dose?
    Pellizzer AM; Krum H
    Aust Fam Physician; 1996 Jul; 25(7):1067-9, 1072-3, 1076-7. PubMed ID: 8768273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Resistance to ACE inhibitors. Myth or reality?].
    Aumont MC; Juliard JM
    Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1008-12. PubMed ID: 11603063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiotensin-converting enzyme inhibitors and/or angiotensin II receptors antagonists in the treatment of arterial hypertension].
    Silance PG
    Rev Med Brux; 2003 Sep; 24(4):A253-6. PubMed ID: 14606289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience.
    Materson BJ; Preston RA
    Arch Intern Med; 1994 Mar; 154(5):513-23. PubMed ID: 8122944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE inhibitors: future perspectives.
    Reid JL
    J Cardiovasc Pharmacol; 1993; 22 Suppl 1():S41-3. PubMed ID: 7507539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC; Hörl WH
    Wien Med Wochenschr; 2001; 151(7-8):160-4. PubMed ID: 11450164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonist?
    McInnes GT
    J Hypertens Suppl; 2001 Jun; 19(1):S61-7. PubMed ID: 11451217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of beta-blockade and ACE inhibitors in the treatment of hypertension.
    Prichard BN; Saul PA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S81-5. PubMed ID: 11527141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.